Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PATHOLOGICAL EXAMINATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL PATHOLOGICAL EXAMINATION MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PATHOLOGICAL EXAMINATION MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 INDUSTRY INSIGHTS
7 REGULATORY FRAMWORK
8 IMPACT OF COVID-19 PANDEMIC ON THE MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION FOR MANUFACTURERS/SERVICE PROVIDERS
8.5 CONCLUSION
9 GLOBAL PATHOLOGICAL EXAMINATION MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIGITAL PATHOLOGY
9.2.1 DIGITAL IMAGING PROCESS
9.2.2 IMAGE ANALYSIS
9.3 TRADITIONAL PATHOLOGY
10 GLOBAL PATHOLOGICAL EXAMINATION MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 REAGENTS & CONSUMABLES
10.2.1 SPECIMEN COLLECTION PRODUCTS
10.2.1.1. CONTAINER-BASED
10.2.1.2. SWAB BASED
10.2.2 ANTIBODIES
10.2.3 MICROARRAYS
10.2.4 STAINS
10.2.5 STAINING PLATFORMS
10.2.6 DETECTION KITS
10.2.7 PROBES
10.2.8 ASSAYS & PANELS
10.2.9 ACCESSORIES KITS
10.2.10 OTHERS
10.3 INSTRUMENTS & SYSTEMS
10.3.1 MICROSCOPE WITH DIGITAL CAMERA
10.3.2 WHOLE SLIDE SCANNERS
10.3.3 ROBOTIC MICROSCOPE
10.3.4 IMAGE ANALYSIS SYSTEM
10.3.5 TISSUE MICROARRAYS
10.3.6 VIRTUAL MICROSCOPE SYSTEMS
10.3.7 DIGITAL SLIDES
10.3.8 STORAGE & COMMUNICATION SYSTEMS
10.3.9 OTHER COMPONENTS
10.4 SOFTWARE
10.4.1 VIEWERS
10.4.2 QUANTIFICATION APPLICATIONS
10.4.3 PATHOLOGY MANAGEMENT SOLUTIONS
10.4.4 CONTROL SOFTWARE
10.4.5 OTHERS
10.5 SERVICES
10.5.1 HISTOLOGY SERVICES
10.5.2 TISSUE EMBEDDING AND SECTIONING
10.5.3 COMPANION DIAGNOSTIC EXPERIENCE
10.5.4 OTHERS
11 GLOBAL PATHOLOGICAL EXAMINATION MARKET, BY SPECIALIZATION
11.1 OVERVIEW
11.2 ANATOMIC PATHOLOGY
11.2.1 HUMAN PATHOLOGY
11.2.2 VETERINARY PATHOLOGY
11.3 SURGICAL PATHOLOGY
11.3.1 HUMAN PATHOLOGY
11.3.2 VETERINARY PATHOLOGY
11.4 CYTOPATHOLOGY
11.4.1 HUMAN PATHOLOGY
11.4.2 VETERINARY PATHOLOGY
11.5 MOLECULAR PATHOLOGY
11.5.1 HUMAN PATHOLOGY
11.5.2 VETERINARY PATHOLOGY
11.6 OTHERS
12 GLOBAL PATHOLOGICAL EXAMINATION MARKET, BY DIAGNOSTIC AREA
12.1 OVERVIEW
12.2 HAEMATOLOGY
12.3 CLINICAL CHEMISTRY
12.4 MICROBIOLOGY TESTING
12.5 IMMUNOLOGY TESTING
12.6 TOXICOLOGY TESTING
12.7 CYTOLOGY TESTING
12.8 MOLECULAR GENETIC PATHOLOGY (MGP)
12.9 OTHERS
13 GLOBAL PATHOLOGICAL EXAMINATION MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 TELECONSULTATION
13.3 DISEASE DIAGNOSIS
13.4 DRUG DISCOVERY & DEVELOPMENT
13.5 BIOANALYTICAL & LAB CHEMISTRY
13.6 CELL & GENE THERAPY
13.7 OTHERS
14 GLOBAL PATHOLOGICAL EXAMINATION MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL LABS
14.3 PUBLIC HEALTH LABS
14.4 PHARMA & BIOTECH COMPANIES
14.5 REFERENCE LABORATORIES
14.6 BLOOD BANKS
14.7 ACADEMIC & RESEARCH INSTITUTES
14.8 DIAGNOSTIC CLINICS
14.9 VETERINARY LABORATORIES
14.1 OTHERS
15 GLOBAL PATHOLOGICAL EXAMINATION MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDERS
15.3 RETAIL SALES
15.4 THIRD PARTY DISTRIBUTOR
16 GLOBAL PATHOLOGICAL EXAMINATION MARKET, BY COUNTRY
GLOBAL PATHOLOGICAL EXAMINATION MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.1.1 NORTH AMERICA
16.1.1.1. U.S.
16.1.1.2. CANADA
16.1.1.3. MEXICO
16.1.2 EUROPE
16.1.2.1. GERMANY
16.1.2.2. FRANCE
16.1.2.3. U.K.
16.1.2.4. ITALY
16.1.2.5. SPAIN
16.1.2.6. RUSSIA
16.1.2.7. TURKEY
16.1.2.8. BELGIUM
16.1.2.9. NETHERLANDS
16.1.2.10. SWITZERLAND
16.1.2.11. REST OF EUROPE
16.1.3 ASIA-PACIFIC
16.1.3.1. JAPAN
16.1.3.2. CHINA
16.1.3.3. SOUTH KOREA
16.1.3.4. INDIA
16.1.3.5. AUSTRALIA
16.1.3.6. SINGAPORE
16.1.3.7. THAILAND
16.1.3.8. MALAYSIA
16.1.3.9. INDONESIA
16.1.3.10. PHILIPPINES
16.1.3.11. REST OF ASIA-PACIFIC
16.1.4 SOUTH AMERICA
16.1.4.1. BRAZIL
16.1.4.2. ARGENTINA
16.1.4.3. REST OF SOUTH AMERICA
16.1.5 MIDDLE EAST AND AFRICA
16.1.5.1. SOUTH AFRICA
16.1.5.2. SAUDI ARABIA
16.1.5.3. UAE
16.1.5.4. EGYPT
16.1.5.5. ISRAEL
16.1.5.6. REST OF MIDDLE EAST AND AFRICA
16.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL PATHOLOGICAL EXAMINATION MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL PATHOLOGICAL EXAMINATION MARKET, SWOT AND DBMR ANALYSIS
19 GLOBAL PATHOLOGICAL EXAMINATION MARKET, COMPANY PROFILE
19.1 3DHISTECH LTD.
19.1.1 COMPANY OVERVIEW
19.1.2 REVENUE ANALYSIS
19.1.3 GEOGRAPHIC PRESENCE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 HEALIO
19.2.1 COMPANY OVERVIEW
19.2.2 REVENUE ANALYSIS
19.2.3 GEOGRAPHIC PRESENCE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 ABBOTT PATHOLOGY
19.3.1 COMPANY OVERVIEW
19.3.2 REVENUE ANALYSIS
19.3.3 GEOGRAPHIC PRESENCE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 NEOGENOMICS LABORATORIES, INC.
19.4.1 COMPANY OVERVIEW
19.4.2 REVENUE ANALYSIS
19.4.3 GEOGRAPHIC PRESENCE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 F. HOFFMANN-LA ROCHE LTD
19.5.1 COMPANY OVERVIEW
19.5.2 REVENUE ANALYSIS
19.5.3 GEOGRAPHIC PRESENCE
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 AGILENT TECHNOLOGIES, INC
19.6.1 COMPANY OVERVIEW
19.6.2 REVENUE ANALYSIS
19.6.3 GEOGRAPHIC PRESENCE
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPMENTS
19.7 BIO SB
19.7.1 COMPANY OVERVIEW
19.7.2 REVENUE ANALYSIS
19.7.3 GEOGRAPHIC PRESENCE
19.7.4 PRODUCT PORTFOLIO
19.7.5 RECENT DEVELOPMENTS
19.8 QUEST DIAGNOSTICS
19.8.1 COMPANY OVERVIEW
19.8.2 REVENUE ANALYSIS
19.8.3 GEOGRAPHIC PRESENCE
19.8.4 PRODUCT PORTFOLIO
19.8.5 RECENT DEVELOPMENTS
19.9 SIEMENS MEDICAL SOLUTIONS USA, INC.
19.9.1 COMPANY OVERVIEW
19.9.2 REVENUE ANALYSIS
19.9.3 GEOGRAPHIC PRESENCE
19.9.4 PRODUCT PORTFOLIO
19.9.5 RECENT DEVELOPMENTS
19.1 TRINITY BIOTECH
19.10.1 COMPANY OVERVIEW
19.10.2 REVENUE ANALYSIS
19.10.3 GEOGRAPHIC PRESENCE
19.10.4 PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPMENTS
19.11 SONIC HEALTHCARE
19.11.1 COMPANY OVERVIEW
19.11.2 REVENUE ANALYSIS
19.11.3 GEOGRAPHIC PRESENCE
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPMENTS
19.12 Q2 SOLUTIONS
19.12.1 COMPANY OVERVIEW
19.12.2 REVENUE ANALYSIS
19.12.3 GEOGRAPHIC PRESENCE
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENTS
19.13 BD
19.13.1 COMPANY OVERVIEW
19.13.2 REVENUE ANALYSIS
19.13.3 GEOGRAPHIC PRESENCE
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENTS
19.14 ABCAM PLC
19.14.1 COMPANY OVERVIEW
19.14.2 REVENUE ANALYSIS
19.14.3 GEOGRAPHIC PRESENCE
19.14.4 PRODUCT PORTFOLIO
19.14.5 RECENT DEVELOPMENTS
19.15 MERCK KGAA
19.15.1 COMPANY OVERVIEW
19.15.2 REVENUE ANALYSIS
19.15.3 GEOGRAPHIC PRESENCE
19.15.4 PRODUCT PORTFOLIO
19.15.5 RECENT DEVELOPMENTS
19.16 LEICA BIOSYSTEMS NUSSLOCH GMBH
19.16.1 COMPANY OVERVIEW
19.16.2 REVENUE ANALYSIS
19.16.3 GEOGRAPHIC PRESENCE
19.16.4 PRODUCT PORTFOLIO
19.16.5 RECENT DEVELOPMENTS
19.17 DHISTECH
19.17.1 COMPANY OVERVIEW
19.17.2 REVENUE ANALYSIS
19.17.3 GEOGRAPHIC PRESENCE
19.17.4 PRODUCT PORTFOLIO
19.17.5 RECENT DEVELOPMENTS
19.18 KONINKLIJKE PHILIPS N.V.
19.18.1 COMPANY OVERVIEW
19.18.2 REVENUE ANALYSIS
19.18.3 GEOGRAPHIC PRESENCE
19.18.4 PRODUCT PORTFOLIO
19.18.5 RECENT DEVELOPMENTS
19.19 BIO LAB DIAGNOSTICS (I) PRIVATE LIMITED.
19.19.1 COMPANY OVERVIEW
19.19.2 REVENUE ANALYSIS
19.19.3 GEOGRAPHIC PRESENCE
19.19.4 PRODUCT PORTFOLIO
19.19.5 RECENT DEVELOPMENTS
19.2 NIHON KOHDEN CORPORATION
19.20.1 COMPANY OVERVIEW
19.20.2 REVENUE ANALYSIS
19.20.3 GEOGRAPHIC PRESENCE
19.20.4 PRODUCT PORTFOLIO
19.20.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
